EA201990129A1 - Таблетированный состав с улучшенным профилем растворения для лечения болезни паркинсона - Google Patents
Таблетированный состав с улучшенным профилем растворения для лечения болезни паркинсонаInfo
- Publication number
- EA201990129A1 EA201990129A1 EA201990129A EA201990129A EA201990129A1 EA 201990129 A1 EA201990129 A1 EA 201990129A1 EA 201990129 A EA201990129 A EA 201990129A EA 201990129 A EA201990129 A EA 201990129A EA 201990129 A1 EA201990129 A1 EA 201990129A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- parkinson
- disease
- treatment
- entacapone
- dissolution profile
- Prior art date
Links
- 238000004090 dissolution Methods 0.000 title abstract 2
- 208000018737 Parkinson disease Diseases 0.000 title 1
- JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 abstract 3
- 229960003337 entacapone Drugs 0.000 abstract 3
- IVTMXOXVAHXCHI-YXLMWLKOSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(2s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 IVTMXOXVAHXCHI-YXLMWLKOSA-N 0.000 abstract 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 abstract 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 abstract 1
- QTAOMKOIBXZKND-PPHPATTJSA-N carbidopa Chemical compound O.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 QTAOMKOIBXZKND-PPHPATTJSA-N 0.000 abstract 1
- 229960004205 carbidopa Drugs 0.000 abstract 1
- 238000009826 distribution Methods 0.000 abstract 1
- 239000008187 granular material Substances 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 abstract 1
- 229960004502 levodopa Drugs 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Настоящее изобретение относится к способу получения фармацевтической комбинации фиксированных доз, таблетки с немедленным высвобождением, содержащей леводопу, карбидопу и энтакапон или их фармацевтически приемлемые соли или гидраты, характеризующейся тем, что энтакапон обладает свойством, которое заключается в очень быстром растворении вследствие применения распределения частиц с малым размером. Также леводопу и карбидопу гранулируют вместе для получения гранулы с одинаковым количеством содержимого, и энтакапон гранулируют отдельно с целью облегчения получения фармацевтической комбинации в виде таблетки.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/TR2016/050292 WO2018034626A1 (en) | 2016-08-18 | 2016-08-18 | Antiparkinson tablet formulation with improved dissolution profile |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201990129A1 true EA201990129A1 (ru) | 2019-05-31 |
EA036784B1 EA036784B1 (ru) | 2020-12-21 |
Family
ID=57047275
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201990129A EA036784B1 (ru) | 2016-08-18 | 2016-08-18 | Таблетированный состав с улучшенным профилем растворения для лечения болезни паркинсона |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP3500246B1 (ru) |
EA (1) | EA036784B1 (ru) |
ES (1) | ES2895054T3 (ru) |
WO (1) | WO2018034626A1 (ru) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111954523A (zh) * | 2018-03-29 | 2020-11-17 | 艾维制药有限责任公司 | 左旋多巴分次剂量组合物及用途 |
WO2022180649A1 (en) * | 2021-02-26 | 2022-09-01 | Msn Laboratories Private Limited, R&D Center | Novel process for the preparation of 2,5-dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine-1-oxide |
CN113081994B (zh) * | 2021-04-20 | 2022-03-22 | 杭州泓友医药科技有限公司 | 一种用于治疗帕金森症的复方药物及其制备方法 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5283352A (en) | 1986-11-28 | 1994-02-01 | Orion-Yhtyma Oy | Pharmacologically active compounds, methods for the preparation thereof and compositions containing the same |
YU213587A (en) | 1986-11-28 | 1989-06-30 | Orion Yhtymae Oy | Process for obtaining new pharmacologic active cateholic derivatives |
AU2807089A (en) | 1987-10-05 | 1989-04-18 | Pharmagyn, Inc. | Tablet for use in the treatment of progesterone deficiency |
FI109453B (fi) | 1999-06-30 | 2002-08-15 | Orion Yhtymae Oyj | Farmaseuttinen koostumus |
US7094427B2 (en) | 2002-05-29 | 2006-08-22 | Impax Laboratories, Inc. | Combination immediate release controlled release levodopa/carbidopa dosage forms |
US20040166159A1 (en) | 2002-05-29 | 2004-08-26 | Chien-Hsuan Han | Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa |
EP2335696A1 (en) * | 2005-06-08 | 2011-06-22 | Orion Corporation | An entacapone-containing oral dosage form |
AR055106A1 (es) | 2005-08-05 | 2007-08-08 | Osmotica Pharmaceutical Argent | Composicion farmaceutica solida de liberacion extendida que contiene carbidopa y levodopa |
CA2635313C (en) | 2005-12-29 | 2013-12-31 | Osmotica Corp. | Triple combination release multi-layered tablet |
UA95954C2 (ru) | 2006-05-31 | 2011-09-26 | Солвей Фармасьютикалс Гмбх | Продолжительное 24-часовое введение в кишечник леводопа/карбидопа |
US20090155369A1 (en) | 2007-12-13 | 2009-06-18 | Laboratorios Lesvi, S.L. | Pharmaceutical composition containing levodopa, entacapone and carbidopa |
RU2485947C2 (ru) | 2008-02-06 | 2013-06-27 | Вокхардт Рисерч Сентер | Фармацевтические композиции энтакапона, леводопы и карбидопы с улучшенной биодоступностью |
-
2016
- 2016-08-18 ES ES16775356T patent/ES2895054T3/es active Active
- 2016-08-18 EA EA201990129A patent/EA036784B1/ru unknown
- 2016-08-18 EP EP16775356.5A patent/EP3500246B1/en active Active
- 2016-08-18 WO PCT/TR2016/050292 patent/WO2018034626A1/en active Search and Examination
Also Published As
Publication number | Publication date |
---|---|
EP3500246A1 (en) | 2019-06-26 |
WO2018034626A1 (en) | 2018-02-22 |
ES2895054T3 (es) | 2022-02-17 |
EA036784B1 (ru) | 2020-12-21 |
EP3500246B1 (en) | 2021-08-04 |
WO2018034626A9 (en) | 2019-01-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX363265B (es) | Forma cristalina i de ibrutinib. | |
NZ592325A (en) | Extended release oral acetaminophen/tramadol dosage form | |
EA201691242A1 (ru) | Фармацевтические композиции, содержащие azd9291 | |
MX2021016109A (es) | Metodos y composiciones particularmente para el tratamiento del trastorno por deficit de atencion. | |
EA201592172A1 (ru) | Проглатываемые таблетки n-ацетилцистеина | |
EA201990129A1 (ru) | Таблетированный состав с улучшенным профилем растворения для лечения болезни паркинсона | |
MX2021002322A (es) | Nuevos metodos. | |
EA201690005A1 (ru) | Состав с модифицированной кинетикой высвобождения | |
PH12017501304A1 (en) | Levodopa and carbidopa intestinal gel and method of use | |
EA201992382A3 (ru) | Пероральная таблетированная фармацевтическая композиция двойного применения на основе сульфатных солей и способы ее применения | |
EA202090913A1 (ru) | Композиция таблеток с модифицированным высвобождением, содержащая мирабегрон | |
MX2022006741A (es) | Formas de estado solido del inhibidor de hdac. | |
SA516370446B1 (ar) | تركيبة صيدلانية مستقرة مضادة للدرن في صورة قرص قابل للتشتت يحتوي على حبيبات إيزونيازيد وحبيبات ريفابنتين، وعملية لتحضيرها | |
MX337488B (es) | Granulos con alto contenido de ibuprofeno sodico, su preparacion y su uso en preparar formas de dosificacion solidas no efervescentes. | |
EA201592297A1 (ru) | Композиции агомелатина, содержащие агомелатин в форме сокристаллов | |
PH12016500120A1 (en) | Anti-tuberculosis stable pharmaceutical composition in a form of a coated tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation | |
MX2018003890A (es) | Composiciones farmaceuticas que contienen un relajante muscular y un antiinflamatorio no esteroideo (aine). | |
MX2018011293A (es) | Composicion farmaceutica de liberacion prolongada que comprende cisteamina o sal de la misma. | |
MX2016006464A (es) | Composicion farmaceutica de una combinacion de clorhidrato de tramadol-etoricoxib para el tratamiento del dolor. | |
PL425832A1 (pl) | Genisteina oraz jej kompozycja do zastosowania w leczeniu choroby Alzheimera | |
IN2013MU03428A (ru) | ||
MX2016017001A (es) | Sistema multiparticulado de liberacion bifasica con prediccion de biodisponibilidad modificada de acemetacina. | |
HRP20210969T1 (hr) | Farmaceutski sastav koji sadrži darunavir i metoda za njegovu pripremu | |
PH12019501607A1 (en) | Tapentadol nasal composition | |
MX2017009660A (es) | Composicion farmaceutica con un rango de relacion entre el clorhidrato de tramadol y el etoricoxib para su administracion para el tratamiento del dolor. |